Palmitoyl tripeptide-38: complete guide

Palmitoyl tripeptide-38 is the lipopeptide in Matrixyl synthe'6. This guide covers its structure, the small published studies, and its safety and regulatory status.

Complete guide5 min read

Key takeaway

PubChem lists palmitoyl tripeptide-38 at 676.0 g/mol. The human studies we found tested it only inside multi-ingredient products, in 32 to 37 women per study. We found no final Cosmetic Ingredient Review (CIR) safety conclusion for it.

At a glance

Article typeComplete guide
Regulatory statusCosmetic / topical“Palmitoyl tripeptide-38 is a cosmetic ingredient, not an FDA-approved drug.” (this article)
ClassSkin & cosmetic
Body systemsSkin & connective tissue
Studies cited3 in this article · 3 across 1 article on Palmitoyl tripeptide-38
Related productsCopper peptides and melanocortin fragments

Palmitoyl tripeptide-38 is a cosmetic ingredient made of palmitic acid joined to a three-amino-acid peptide: lysine, an oxidized methionine and lysine. It is the peptide in the trade-name solution Matrixyl synthe’6. This guide covers its structure, published studies and safety status. Sources were checked on November 17, 2026.

Quick answer: Palmitoyl tripeptide-38 is Pal-Lys-Met(O2)-Lys, a fatty-acid-linked tripeptide. CosIng lists it as a skin conditioning ingredient. Published studies tested finished serums and creams with several actives, so its own effect is unknown. It is a cosmetic ingredient, not a drug.

Vitrapep does not sell palmitoyl tripeptide-38; this page is a reference summary of published research and regulatory information.

What is palmitoyl tripeptide-38?

Palmitoyl tripeptide-38 is a lipopeptide, a short peptide joined to a fatty acid. CosIng defines it as “the reaction product of palmitic acid and Tripeptide-38” (CosIng, 2026). PubChem lists the formula C33H65N5O7S and a molecular weight of 676.0 g/mol (PubChem CID 71587932). Our peptide primer explains the basics.

PubChem gives the sequence as Pal-Lys-Met(O2)-Lys. The middle residue is methionine with its sulfur fully oxidized to a sulfone; PubChem’s systematic name shows this as a methylsulfonyl group. A 2012 CIR draft described tripeptide-38 as a synthetic peptide “containing lysine and methionine” (CIR draft, 2012).

PubChem lists Matrixyl synthe’6 as a synonym. Croda’s product page gives the INCI listing for Matrixyl synthe’6 as glycerin, water, hydroxypropyl cyclodextrin and palmitoyl tripeptide-38 (Croda, 2026). Croda’s Volulip also lists it, alongside Portulaca pilosa extract (Croda Volulip, 2026). Our Matrixyl guide explains how the Matrixyl names differ.

Table 1

Palmitoyl tripeptide-38: key facts

Fact Detail
INCI name Palmitoyl Tripeptide-38
Structure type Lipopeptide: palmitoyl group on a linear three-amino-acid peptide
Sequence Pal-Lys-Met(O2)-Lys (methionine as its sulfone)
Molecular formula C33H65N5O7S
Molecular weight 676.0 g/mol
Main cosmetic function (CosIng) Skin conditioning
Trade name(s) Matrixyl synthe’6; also listed in Volulip

How does palmitoyl tripeptide-38 work?

Its mechanism has not been shown in an independent, peer-reviewed laboratory study that we could find. The clearest published description sits in a 2020 clinical paper. Its authors call it “one such matrikine-mimetic peptide,” derived from repair signaling sequences.

That paper says the peptide stimulates the synthesis of six matrix molecules: three collagen types, hyaluronic acid, fibronectin and laminin. The authors cite a patent for this statement, not a published experiment (Lintner et al., 2020).

What is palmitoyl tripeptide-38 used for?

CosIng lists one function: skin conditioning. FDA registration data cited in the 2012 CIR draft showed 1 reported use of palmitoyl tripeptide-38, in a leave-on product. Newer use counts were not found.

Under US law, intended use decides whether a product is a cosmetic or a drug. Claims to affect the structure or function of the body can make a product a drug (FDA, 2024).

What does the research show?

Three human studies name palmitoyl tripeptide-38. Each tested a product with several actives, so none isolates the peptide. Two were open-label with no control group.

Vitamin C and E serum (2020). An open-label study enrolled 35 women aged 49 to 74. The serum combined L-ascorbic acid, tocopheryl acetate and palmitoyl tripeptide-38. At day 56, roughness measures fell 8% to 9%, redness fell 9% and skin-tone evenness rose 8%. The authors note the lack of a control group as a limitation. The serum’s maker funded the study, and the authors consult for it (Lintner et al., 2020).

Multi-active serum (2016). Scientists at a Spanish skincare company tested a serum with apple stem cell extract, creatine, urea and palmitoyl tripeptide-38. In 32 women with sensitive skin, they reported an anti-wrinkle effect in 71% and higher dermal density and elasticity. In lab tests on aged fibroblasts, the serum lowered mitochondrial oxidant production (Sanz et al., 2016).

Multi-ingredient moisturizer (2015). An open-label trial in 37 women aged 35 to 60 tested a multi-ingredient moisturizer. It contained plant extracts, a vitamin C ester, ubiquinone and a peptide blend including palmitoyl tripeptide-38. Clinical grading scores improved versus baseline at week 8 and more by week 12 (Herndon et al., 2015).

What safety data exist?

We found no final CIR safety assessment that covers palmitoyl tripeptide-38. CIR’s 2012 draft review of palmitoyl oligopeptides listed it. The 2014 final report narrowed its safety conclusion to three sequences, GHK, VGVAPG and GQPR, which do not include tripeptide-38 (CIR, 2014). CosIng lists no EU restrictions and no SCCS opinion for it.

Tolerance data come from the product studies above. The 2020 serum study reported that the product was well tolerated, with no adverse effects attributed to it. The 2015 moisturizer trial found no significant rise in any tolerability score versus baseline. These are small studies of whole products, not ingredient safety tests.

Under US law, the responsibility sits with companies. FDA states that “Companies and individuals who manufacture or market cosmetics have a responsibility to ensure the safety of their products” (FDA, 2026).

What is palmitoyl tripeptide-38’s regulatory status, and how is it used in research?

In the United States, cosmetic products and ingredients, other than color additives, need no FDA approval before sale (FDA, 2025). Palmitoyl tripeptide-38 is a cosmetic ingredient, not an FDA-approved drug.

The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) became law on December 29, 2022. It added facility registration, product listing, serious adverse event reporting, safety substantiation records and mandatory recalls (FDA Voices, 2026). In the EU, CosIng lists the ingredient with an active status.

In published research, palmitoyl tripeptide-38 appears mainly as one active in finished-product tests like those above. For the wider class, see peptides in skincare.

Frequently asked questions about palmitoyl tripeptide-38

Is palmitoyl tripeptide-38 the same as Matrixyl synthe’6?

Not exactly. Matrixyl synthe’6 is a trade-name solution whose INCI listing includes palmitoyl tripeptide-38 with glycerin, water and hydroxypropyl cyclodextrin.

Is it the same as Matrixyl or Matrixyl 3000?

No. Matrixyl is palmitoyl pentapeptide-4. Matrixyl 3000 lists palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.

What does Met(O2) mean?

It marks methionine whose sulfur carries two extra oxygen atoms, a form called methionine sulfone.

Has CIR reviewed palmitoyl tripeptide-38?

It appeared in a 2012 CIR draft, but the 2014 final conclusion does not cover it. We found no later CIR conclusion.

Is palmitoyl tripeptide-38 approved by the FDA?

No. FDA does not approve cosmetic ingredients, other than color additives, before they go on the market.

What to know now

  • Structure: Pal-Lys-Met(O2)-Lys; C33H65N5O7S; 676.0 g/mol.
  • Trade name: Matrixyl synthe’6; also listed in Volulip.
  • Function: CosIng lists skin conditioning.
  • Evidence: three small multi-ingredient studies; none isolates the peptide.
  • Safety: no final CIR conclusion found; product studies reported good tolerance.
  • Status: a cosmetic ingredient, not an FDA-approved drug.

What we’re watching

FDA rules under MoCRA. The MoCRA page, updated October 29, 2026, lists good manufacturing practice and fragrance allergen labeling rules that the law requires (FDA, 2026). Related guides: palmitoyl tetrapeptide-7 and tripeptide-10 citrulline.

More for skin & connective tissue

All 23 compounds for skin & connective tissue

Sources: National Center for Biotechnology Information 2026, PubChem compound summary for CID 71587932, palmitoyl tripeptide-38; European Commission 2026, CosIng: Palmitoyl tripeptide-38; Croda 2026, Matrixyl synthe’6; Croda 2026, Volulip; Cosmetic Ingredient Review 2012, Safety assessment of palmitoyl oligopeptides as used in cosmetics; Cosmetic Ingredient Review 2014; Lintner 2020, Journal of Cosmetic Dermatology, 19; Sanz 2016, Journal of Cosmetic Dermatology, 15; Herndon 2015, Journal of Drugs in Dermatology, 14; U.S. Food and Drug Administration 2025, FDA authority over cosmetics: How cosmetics are not FDA-approved, but are FDA-regulated; U.S. Food and Drug Administration 2024, Is it a cosmetic, a drug, or both? (Or is it soap?); Kozlowski 2026, How FDA is implementing landmark cosmetics legislation to positively impact public health; U.S. Food and Drug Administration 2026, Modernization of Cosmetics Regulation Act of 2022 (MoCRA). All 13 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 71587932, palmitoyl tripeptide-38. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/71587932
  2. European Commission. (2026). CosIng: Palmitoyl tripeptide-38 (substance ID 85966). Retrieved November 17, 2026, from https://ec.europa.eu/growth/tools-databases/cosing/details/85966
  3. Croda. (2026). Matrixyl synthe’6 (product page). Retrieved November 17, 2026, from https://www.crodabeauty.com/en-gb/products/product/3046-matrixyl_1_synthe_1_6
  4. Croda. (2026). Volulip (product page). Retrieved November 17, 2026, from https://www.crodabeauty.com/en-gb/products/product/3044-volulip
  5. Cosmetic Ingredient Review. (2012, August 13). Safety assessment of palmitoyl oligopeptides as used in cosmetics (scientific literature review, draft). https://www.cir-safety.org/sites/default/files/palmit072012slr.pdf
  6. Cosmetic Ingredient Review. (2014, June 30). Safety assessment of tripeptide-1, hexapeptide-12, their metal salts and fatty acyl derivatives, and palmitoyl tetrapeptide-7 as used in cosmetics (final report). https://www.cir-safety.org/sites/default/files/tripep062014final.pdf
  7. Lintner, K., Gerstein, F., & Solish, N. (2020). A serum containing vitamins C & E and a matrix-repair tripeptide reduces facial signs of aging as evidenced by Primos® analysis and frequently repeated auto-perception. Journal of Cosmetic Dermatology, 19(12), 3262-3269. https://doi.org/10.1111/jocd.13770
  8. Sanz, M. T., et al. (2016). Biorevitalizing effect of a novel facial serum containing apple stem cell extract, pro-collagen lipopeptide, creatine, and urea on skin aging signs. Journal of Cosmetic Dermatology, 15(1), 24-30. https://doi.org/10.1111/jocd.12173
  9. Herndon, J. H., Jr., et al. (2015). An open label clinical trial of a multi-ingredient anti-aging moisturizer designed to improve the appearance of facial skin. Journal of Drugs in Dermatology, 14(7), 699-704. https://pubmed.ncbi.nlm.nih.gov/26151786/
  10. U.S. Food and Drug Administration. (2025). FDA authority over cosmetics: How cosmetics are not FDA-approved, but are FDA-regulated (content current as of 11/18/2025). Retrieved November 17, 2026, from https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated
  11. U.S. Food and Drug Administration. (2024). Is it a cosmetic, a drug, or both? (Or is it soap?) (content current as of 09/11/2024). Retrieved November 17, 2026, from https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
  12. Kozlowski, S. (2026). How FDA is implementing landmark cosmetics legislation to positively impact public health. FDA Voices, U.S. Food and Drug Administration. Retrieved November 17, 2026, from https://www.fda.gov/news-events/fda-voices/how-fda-implementing-landmark-cosmetics-legislation-positively-impact-public-health
  13. U.S. Food and Drug Administration. (2026). Modernization of Cosmetics Regulation Act of 2022 (MoCRA) (content current as of 10/29/2026). Retrieved November 17, 2026, from https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra